Sign in to continue:

Saturday, March 14th, 2026

Vuzix Reports 2025 Financial Results, Secures $20M Quanta Investment, and Advances Waveguide & OEM Smart Glasses Growth




Vuzix Reports 2025 Financial Results – Key Highlights for Investors

Vuzix Reports 2025 Financial Results and Outlines Strategic Growth Initiatives for 2026

Key Highlights

  • 2025 Revenue Growth: Vuzix achieved modest revenue growth in 2025, with total revenues rising to \$6.3 million from \$5.8 million in 2024. Product sales increased by 4% to \$4.7 million, primarily due to higher unit sales of M400 smart glasses. Engineering services revenues also grew to \$1.6 million from \$1.3 million, boosted by increased demand from defense and security agencies.
  • Significantly Improved Gross Profit/Loss: The company reduced its gross loss to \$1.1 million in 2025, compared to a gross loss of \$5.6 million in 2024, primarily due to a significant reduction in inventory obsolescence provisions (down from \$4.2 million in 2024 to \$0.5 million in 2025).
  • Substantial Reduction in Net Loss: Net loss attributable to common shareholders narrowed sharply to \$32.3 million (\$0.42 per share) for 2025, versus \$73.5 million (\$1.08 per share) in 2024. This improvement was largely driven by reduced operating expenses and the absence of the large \$30.3 million impairment on intangible assets and equity investments that occurred in 2024.
  • Operating Expenses Trends:
    • Research & Development: R&D spending increased 31% to \$12.6 million, reflecting continued investments in the LX1 smart glasses and waveguide product development.
    • Selling & Marketing: Expenses decreased by 33% to \$5.5 million, mainly due to reductions in bad debt expense and headcount-related costs.
    • General & Administrative: Down 32% to \$11.6 million, driven by a \$4.9 million drop in non-cash stock-based compensation expenses.
  • Cash Position: As of December 31, 2025, Vuzix had \$21.2 million in cash and cash equivalents, and working capital of \$22.3 million. Operating cash usage decreased by approximately \$5.0 million year-over-year, with \$18.8 million used in 2025 versus \$23.7 million in 2024.
  • Major Operational Milestones:
    • Quanta Computer Partnership: Vuzix met yield and production targets, securing the full \$20 million equity investment from Quanta and advancing their joint supply and sales relationship. This funding is a critical validation of Vuzix’s technology and growth prospects.
    • Strategic Shift: The company is evolving from a branded smart glasses provider to a technology and solutions supplier, focusing on OEM smart glasses, waveguides, and display systems. This foundational shift is backed by expanding engagement with strategic partners and defense/government clients.
  • Management Outlook for 2026: Vuzix expects 2026 to deliver a more diversified business, leveraging opportunities in OEM custom smart glasses programs, defense and government agency initiatives, and waveguide-related activities. The “Made in the USA” waveguide design and manufacturing is seen as a competitive advantage, especially in defense and security markets. The company plans to continue investing in waveguide innovation and strategic partnerships.

Potential Share Price Sensitive Information

  • Secured \$20 Million Strategic Investment from Quanta Computer: This capital infusion and strengthened partnership enhance Vuzix’s financial flexibility and market credibility, and could be a catalyst for increased shareholder value.
  • Significant Reduction in Net Loss and Improved Operating Leverage: The narrowing of losses, along with reduced inventory write-downs and lower operating cash burn, may positively impact investor sentiment.
  • Strategic Business Evolution: Vuzix’s shift toward OEM and defense/government markets, and away from reliance on branded product sales, signals a new growth trajectory with potentially higher-margin opportunities and larger addressable markets.
  • Focus on Defense and Security Markets: Management highlighted defense and security as increasingly important, driven by Vuzix’s U.S.-based manufacturing and technology, which may open doors to government contracts and stable revenue streams.
  • Strong Cash Position: With over \$21 million in cash and improved cash usage, the company is better positioned to weather market volatility and invest in future growth.

Full Financial Details

Q4 2025 Q4 2024 FY 2025 FY 2024
Sales – Products \$1,411k \$1,069k \$4,677k \$4,487k
Sales – Engineering Services \$832k \$204k \$1,604k \$1,267k
Total Sales \$2,243k \$1,272k \$6,281k \$5,755k
Gross Profit (Loss) \$375k (\$4,953k) (\$1,062k) (\$5,600k)
Net Loss Attributable to Common Shareholders (\$8,653k) (\$13,656k) (\$32,335k) (\$73,538k)
Loss Per Share (\$0.12) (\$0.16) (\$0.42) (\$1.08)
Cash & Cash Equivalents \$21,200k N/A
Operating Cash Usage (\$18,800k) (\$23,700k)

Conference Call Details

  • Date: Thursday, March 12, 2026
  • Time: 4:30 p.m. Eastern Time (ET)
  • Webcast: https://ir.vuzix.com/
  • Dial-in (US/Canada): 877-709-8150 | International: 201-689-8354
  • Replay available for 30 days (Replay ID: 13759109)

About Vuzix

Vuzix is a leading developer of AI-powered smart glasses, waveguides, and AR technologies for enterprise, medical, defense, security, and consumer markets. The company holds over 500 patents and has won over 20 CES innovation awards. Vuzix is publicly traded (NASDAQ: VUZI) with offices in Rochester, NY, and Japan.

Disclaimer

This article includes forward-looking statements, which involve risks and uncertainties. Actual results may differ materially from those expressed or implied herein. Investors should review all official filings and risk factors disclosed by Vuzix with the United States Securities and Exchange Commission and applicable Canadian regulators. This article does not constitute investment advice.




View Vuzix Corp Historical chart here



MFA Financial, Inc. 2025 Annual Report and Financial Statements – Real Estate Investment Trust (REIT) Overview

MFA Financial, Inc. 2025 Annual Report – Key Insights for In...

Cardiff Oncology Reports Positive Phase 2 Results for Onvansertib in RAS-Mutated mCRC and Provides 2025 Financial Update

Cardiff Oncology Reports Full Year 2025 Results & Business U...

INNO HOLDINGS INC. Form 8-K Filing Details: Nasdaq Listing, Company Information, and SEC Compliance 472830

Inno Holdings Inc. 2026 Annual Stockholders Meeting – Key De...

   Ad